Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry - 16/04/21
, Miha Cercek b, Lisette Okkels Jensen c, Oliver Bushljetikj d, Lucian Calmac e, Tom Johnson f, Montserrat Gracida Blancas g, Vladimir Ganyukov h, Wojtek Wojakowski i, Clemens von Birgelen j, Alexander IJsselmuiden k, Bernardo Tuccillo l, Francesco Versaci m, Jurrien Ten Berg n, Mika Laine o, Tim Berkout p, Gianni Casella q, Petr Kala r, Bernabé López Ledesma s, Victor Becerra t, Roberto Padalino u, Andrea Santucci v, Xavier Carrillo w, Alessandra Scoccia x, Giovanni Amoroso bl, Arpad Lux y, Tomas Kovarnik z, Periklis Davlouros aa, Gabriele Gabrielli ab, Xacobe Flores Rios ac, Nikola Bakraceski ad, Sébastien Levesque ae, Vincenzo Guiducci af, Michał Kidawa ag, Lucia Marinucci ah, Filippo Zilio ai, Gennaro Galasso aj, Enrico Fabris ak, Maurizio Menichelli al, Stephane Manzo am, Gianluca Caiazzo an, Jose Moreu ao, Juan Sanchis Forés ap, Luca Donazzan aq, Luigi Vignali ar, Rui Teles as, Pierfrancesco Agostoni at, Francisco Bosa Ojeda au, Heidi Lehtola av, Santiago Camacho-Freiere aw, Adriaan Kraaijeveld ax, Ylitalo Antti ay, Gabriella Visconti az, Iñigo Lozano Martínez-Luengas ba, Bruno Scheller bb, Dimitrios Alexopulos bc, Raul Moreno bd, Elvin Kedhi be, Giuseppe Uccello bf, Benjamin Faurie bg, Alejandro Gutierrez Barrios bh, Fortunato Scotto Di Uccio l, Bor Wilbert n, Giuliana Cortese bi, Maurits T. Dirksen p, Guido Parodi bj, Monica Verdoia bk
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study.
Methods |
STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission.
Results |
Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51–0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33–0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084–0.14], p < 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI therapy, both at admission or in-hospital, showed no prognostic effect.
Conclusions |
This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.
Le texte complet de cet article est disponible en PDF.Keywords : Renin-Angiotensin System inhibitors, ST-segment elevation myocardial infarction, Mortality, COVID-19, Percutaneous coronary intervention
Plan
Vol 138
Article 111469- juin 2021 Retour au numéro
Article précédent
- Parecoxib improves atherosclerotic plaque stability by suppressing inflammation and inhibiting matrix metalloproteinases production
- Chao Gong, Yu Qi, Yang Xu, Xiruo Tang, Feng Liang, Lianhua Chen
- Rhizoma drynariae total flavonoids inhibit the inflammatory response and matrix degeneration via MAPK pathway in a rat degenerative cervical intervertebral disc model
- Kai Zhao, Min Chen, Ting Liu, Panpan Zhang, Sheng Wang, Xiangguo Liu, Qunan Wang, Jie Sheng
Bienvenue sur EM-consulte, la référence des professionnels de santé.